I
schemic events in the brain occur because of vessel occlusion by cholesterol-rich plaque or thrombus, which restricts blood flow. Cerebral ischemia can lead to neuronal death in those areas downstream of the occlusion and a consequent deficit in cognitive function. Current tools used to mitigate tissue damage caused by acute thrombotic stroke involve the use of aspirin or reperfusion by fibrinolytic treatment such as tissue plasminogen activator, but this must be administered within the first several hours of ischemia. 1, 2 Intravenously administered tissue plasminogen activator, in fact, remains one of the few therapies for acute ischemic stroke. 3, 4 Inflammation further contributes to the detrimental effects of cerebral ischemia, with neutrophils, macrophages, and T cells composing the major component of infiltrating cells. 5, 6 Further innovations into more specific and localized treatments capable of targeting inflammation and thrombosis apart from hemostasis are necessary.
One molecular target that is being considered for antithrombotic and anti-inflammatory therapeutic development includes ecto-apyrases, which limit inflammation and thrombosis by enzymatically degrading extracellular nucleotides. [7] [8] [9] [10] [11] [12] Of these ecto-apyrases, ectonucleoside triphosphate diphosphohydrolase-1 (CD39) is the dominant form expressed on the plasmalemma of various cell types, including endothelial cells and various leukocyte populations, and is responsible for dissipating the proinflammatory ATP and prothrombotic ADP to form AMP. 10, [13] [14] [15] CD39-mediated degradation of prothrombotic and proinflammatory signals acts locally 16 and may be less likely to increase hemorrhagic risk.
Here we have used a well-established photothrombotic middle cerebral artery occlusion (MCAO) model of cerebral ischemia. [17] [18] [19] [20] Mice were injected with rose bengal dye, and the MCA was permanently occluded by illuminating the vessel with a laser. This model was used because it results in the intraluminal development of a highly localized platelet-rich thrombus without mechanical disruption of endothelium. This model was used to examine the effects of augmentation of endogenous CD39 expression in ischemic stroke. The MCA was chosen as the occlusion target because most ischemic strokes in humans occur in the MCA territory, 21 and the MCAO model described previously was chosen for its high level of reproducibility. To test our hypothesis, we have developed a floxed CD39 transgenic mouse in which we create progeny that either globally or selectively overexpress CD39 in specific cell populations.
METHODS Animal Studies
All procedures performed on animals were in accordance with institutional guidelines.
Generation of Transgenic Mice
C57BL/6 mice (Jackson Laboratories) were used to generate mice that selectively expressed a human CD39 transgene in addition to their endogenous expression of murine CD39. The human gene was preferred over murine CD39 to retain the ability to differentiate between the transgene and the endogenous gene. The protein products of these 2 sequences both express all apyrase conserved regions and have preserved apyrase activity. 22, 23 A backbone construct (pcall-2, a gift from the Lobe laboratory) was modified. 24, 25 A description of the final construct is as follows: a CAG promoter followed by 2 LoxP sequences flanking 3 repetitions of a polyA sequence, followed by the starting sequence and full-length human CD39 cDNA ( Figure 1A ). The sequence was purified and microinjected into fertilized eggs. Transgenic founders were identified by a specific polymerase chain reaction (PCR) screen probing human CD39 DNA: Forward primer, 5' ACA GGC GTG GTG CAT CAA GTA GAA 3' and reverse primer, 5' CCT GGC ACC CTG GAA GTC AAA G -3' (Figure 1B) .
Stable colonies were established and maintained before breeding to EIIA-Cre mice. EIIA-Cre mice have Cre expression driven by the EIIA promoter and are often used when generating mice that express transgenes globally, including in the germ line. 26 Offspring of these breeding pairs generated mice expressing human CD39 globally. Mice carrying the floxed polyA sequence were subsequently bred to LysM-Cre mice (Jackson Laboratories) so that offspring overexpress human
Clinical Perspective
What Is New?
• CD39 is an ectoenzyme with apyrase activity, which cleaves ATP and ADP to form AMP, which is, in turn, converted to adenosine by CD73.
• CD39 is expressed on the surface of myeloid and vascular endothelial cells, where it dissipates high local concentrations of ATP and ADP, which would otherwise serve as potent proinflammatory and prothrombotic signals, respectively. • In this work, for the first time, we show that the genetic overexpression of CD39 limits the brain infarct volume and neurological deficits caused by cerebral ischemia.
What Are the Clinical Implications?
• In our model of permanent middle cerebral artery occlusion, CD39 overexpression reduced edema, infarct volume, and inflammation, with corresponding improvements in neurological outcomes compared with control mice.
• Overexpression of CD39 in only myeloid cells also reduced cerebral infarct volume.
• Amplification of endogenous CD39 expression or even administration of exogenous circulating CD39 could be of future interest as a therapeutic target for minimizing ischemic injury caused by cerebral ischemia. A, A map of the plasmid used to generate CD39 transgenic mice. CD39 was inserted directly after the second loxp site. B, Transgenic mice were identified by polymerase chain reaction (PCR) using primers probing for human CD39. Of 17 potential mice, 5 were identified as transgenic founders. C, Total RNA was isolated from bone marrow of naïve wild type (WT) and transgenic mice and probed with human or mouse CD39 primers in a qualitative PCR assay. Results were normalized to mouse β-actin. D, Total protein was purified from hearts of naïve WT and transgenic mice and probed with anti-CD39 antibodies by Western blot and normalized to α-actin expression. E, Total protein was purified from brains, lungs, livers, and spleens of 3 naïve WT and 3 transgenic mice and probed with anti-CD39 antibodies by Western blot and normalized to β-actin expression. F, Bone marrow was harvested from both WT and transgenic mice, macrophages were grown, and phosphatase activity was measured. ATP or ADP was added as a substrate to live cells, and free phosphate generation was quantified. *P<0.05, **P<0.01, ****P<0.0001.
CD39 in myeloid lineage (LysM) cells and are referred to here as LysM-Cre transgenic mice.
MCAO Model
Naïve 8-to 13-week-old male C57BL/6 mice were anesthetized using 2% isoflurane mixed with oxygen and retro-orbitally administered rose bengal dye (1 mg/25 g body weight dissolved in saline). An incision was made above the left eye, exposing the temporalis muscle. A hole was drilled into the calvarium to visualize the MCA. The MCA was exposed to a 542-nm neon laser to form a thrombus, resulting in permanent focal ischemia. To confirm the occlusion, MCA bloodflow was monitored throughout the surgery using a laser Doppler flow probe (Transonic Systems Inc.). Occlusion was defined as 80% reduction in blood flow sustained for 10 minutes. 19 The skin was then closed, and mice were allowed to recover from surgery under a heat lamp and then returned to clean cages. Mice were euthanized 6 hours, 48 hours, or 7 days later for end point analyses.
Complete Blood Count
Naïve 8-to 13-week-old male C57BL/6 mice, the same age range as all other mice used in other experiments described herein, were anesthetized using 2% isoflurane mixed with oxygen, and blood was drawn into tubes containing sodium citrate (Sigma). Blood was then analyzed using a HemaVet cell analyzer (Drew Scientific).
Heart Rate and Blood Pressure Measurements
Mice were acclimatized for 2 days before radiotelemetric heart rate and blood pressure measurements. Mice then underwent MCAO as described, and blood pressure and heart rate were measured again. Final measurements of blood pressure were taken 7 or 9 days after MCAO.
Quantitative Real Time-PCR (qRT-PCR)
qRT-PCR was used to quantify RNA levels. Organs were harvested from transgenic or age-matched wild-type (WT) C57BL/6 mice and immediately stored in measured volumes of RNAlater (Qiagen) at -80°C until ready for RNA isolation. Samples were cut to a weight of 30 mg, and total RNA was isolated using RNAeasy kits (Qiagen). cDNA was made using cDNA synthesis kits (Applied Biosystems). qRT-PCR was carried out using a 7000 detection system (Applied Biosystems) with 2x Universal Mastermix and primers for human CD39 or mouse CD39 and mouse β-actin (Applied Biosystems). All data were normalized to β-actin.
Whole-Cell Protein Isolation
Organs were harvested from transgenic or age-matched WT C57BL/6 mice and immediately homogenized with a handheld tissue homogenizer in ice-cold RIPA buffer (25 mM Tris-HCL, 150 mM NaCl, 0.1% SDS, 0.1% Triton-X100, with all reagents from Sigma) containing protease inhibitor (Roche). Samples were incubated on ice for 20 minutes before centrifugation on a desktop centrifuge for 10 minutes at 13 000g at 4°C. Resulting supernatants were transferred to new tubes. Protein concentrations of total protein obtained from tissue lysates were determined by a colorimetric protein assay based on the Bradford method (Bio-Rad). Protein samples were flash frozen in aliquots and stored at -80°C.
Western Blot Assay
Total protein was quantified and added to 4x sample buffer (Invitrogen), boiled for 3 minutes at 100°C, separated by 10% SDS-PAGE, and electrophoretically transferred onto polyvinylidene difluoride membranes (Invitrogen). Membranes were probed with mouse monocolonal anti-CD39 IgG 1 antibodies (Abcam) and horseradish peroxidase-conjugated antimouse antibodies (Sigma) and then detected using the enhanced chemiluminescence detection system (Amersham Biosciences). Blots were then washed and probed with mouse monoclonal α-or β-actin IgG 1 conjugated to peroxidase (Sigma) and then detected using enhanced chemiluminescence.
Multiplex Cytokine Assay
Ischemia was induced in age-matched male WT and transgenic mice; 6 hours later, ipsilateral (ischemic) and contralateral cerebral hemispheres were harvested. Total protein was immediately collected by homogenizing tissue in ice-cold RIPA buffer (without ionic detergent) using a handheld homogenizer. Samples were snap frozen in liquid nitrogen until just before initiation of the assay. Samples were gently thawed on ice and then centrifuged at 13 000g on a desktop centrifuge at 4°C for 10 minutes. Supernatants were collected into fresh microcentrifuge tubes. A 96-well filter plate provided in the mouse cytokine panel kit (Invitrogen) was prepared according to manufacturer instructions. Briefly, the filters were incubated with wash buffer, and beads were sonicated and evenly distributed into each well. Duplicate standards were used, and total protein in samples was measured for normalization. After incubation with a biotinylated antibody and streptavidin, a Luminex 100 was used to read the plate.
Magnetic Resonance Imaging (MRI)
Forty-eight hours after inducing cerebral ischemia before brain harvest, mice were anaesthetized with a mixture of 2% isoflurane and air and then placed in a 7.0 T Varian MR scanner (183-mm horizontal bore). Body temperature was maintained at 37°C with heated air. A double-tuned volume radio-frequency coil was used to scan the heads of the mice, and axial T 2 -weighted images were acquired using a spin-echo sequence. Repetition time/effective echo time was 4000/40 ms, field size was 30 x 30 mm, matrix was 128 x 128, slice thickness was 0.5 mm, slice spacing was 0 mm, and 25 slices were taken for each brain. Infarct volumes were then calculated under blinded conditions.
Neurological Deficit Scoring
A 5-point scoring system was used to assess mice 48 hours after MCAO 27 : 1, normal function; 2, flexion of the torso and contralateral forelimb on lifting of the animal by the tail; 3, circling to the contralateral side with normal posture at rest; 4, leaning to the contralateral side at rest; and 5, no spontaneous motor activity.
Flow Cytometry
Forty-eight hours after MCAO, brains were harvested. The cerebellum was excluded, and then hemispheres were separated into individual dishes. Brains were washed with sterile PBS on ice and minced with scissors. Samples were then transferred into gentleMACS tubes (Miltenyi), and cells were dissociated using a gentleMACS dissociator (Miltenyi). Samples were then passed through a sterile 18 g syringe 10 times to obtain a single-cell suspension. Red blood cells were lysed by incubating samples with ammonium-chloride-potassium (ACK) lysis buffer (Invitrogen) for 6 minutes at room temperature in the dark. Samples were then washed and mixed with a 30% Percoll solution and centrifuged at 1400g at 4°C for 10 minutes to separate myelin. Cells were then washed twice in FACS buffer (0.5% FBS, 0.1% sodium azide in PBS), and 100 000 cells were distributed into each tube for antibody staining. 
Immunostaining
Whole brains of mice were harvested 6 hours, 48 hours, or 7 days after MCA occlusion, perfused with PBS, and embedded in Tissue-Tek OCT (Sakura Finetek). They were then frozen at -80°C before sectioning. Coronal sections were cut to a thickness of 10 μM and mounted on glass slides. Sections were kept at -80° C until staining. Slides were allowed to warm briefly before fixation in ice-cold acetone for 10 minutes. Slides were then stained using the Vectastain Elite kit for mouse-derived antibodies, and the signal was amplified using a tyramide signal amplification kit (Perkin-Elmer). CD39, P 2 X 7 receptors, tumor necrosis factor α (TNFα), and Iba-1 were detected using primary monoclonal antibodies (Abcam), and 4',6-diamidino-2-phenylindole was used as a counterstain.
Isolation of Bone Marrow-Derived Macrophages
Bone marrow-derived macrophages were harvested from globally transgenic and WT C57BL/6 mice. Briefly, after humane euthanasia of mice, femurs were isolated and sterilized, and both ends of the bone were severed. Femurs were flushed through with sterile media (DMEM-F12, 10% FBS, 10 mM glutamine) and then spun down at 190g for 10 minutes. Cells were suspended in cell culture medium and grown with granulocytemacrophage colony-stimulating factor overnight. All media and floating cells were transferred and incubated for 3 days. More granulocyte-macrophage colony-stimulating factor was added to media, after which cells were incubated for 4 more days. All cells were then split into appropriate experimental wells, and no further passaging was performed.
Malachite Green Assay to Measure Apyrase Activity
Bone marrow-derived macrophages were harvested from WT and CD39 globally TG mice and plated in 24-well plates (Corning). Cells were washed twice in PBS before the addition of ATP or ADP. Supernatants were collected and transferred to a flat-bottom 96-well plate. Standards were run alongside samples and prepared using serial dilutions of a solution of known concentration of phosphate into the same background buffer as the samples being measured. Last, the working solution for the malachite green assay was added (Bioassay Systems). Plates were incubated for 25 minutes before reading O.D. measurements at 620 nm.
Statistics
Figures and tables comparing 2 groups were analyzed by a Student's t test. Data are shown as mean +/-SEM with the exception of Figure I in the online-only Data Supplement, which is presented as mean +/-SD. A mixed-effect linear regression model was used to compare groups of animals for experiments in which the contralateral hemisphere was used as the control for the ipsilateral (stroked) hemisphere. Differences were considered significant if P was <0.05, except for the multiplex protein array analysis. For the multiplex protein array analysis, using the Bonferonni correction, differences were considered significant if P was <0.0025.
RESULTS

Identification of Transgenic Mice
Conditional transgenic CD39 mice were generated to investigate the protective nature of CD39 in the event of cerebral ischemia. A backbone containing a floxedstop sequence in front of the start codon ( Figure 1A ) was used to generate transgenic mice in a pure C57BL/6 background. Five transgenic founders were identified using a PCR screen for the inserted transgene ( Figure 1B ). Mice were then bred to EIIA-Cre mice with a C57BL/6 background, and transgenic offspring expressing human CD39 were identified using a second PCR screen. Bone marrow was isolated from these mice to measure human CD39 mRNA expression in tissue. TG mice expressed human CD39 mRNA, and endogenous levels of murine CD39 were no different from WT C57BL/6 mice (Figure 1C) . Western blots comparing tissue of WT mice to transgenic mice shows that CD39 is ubiquitously overexpressed across a panel of different organ tissues ( Figure 1D and E) . To confirm the functional significance vis-à-vis enzymatic (apyrase) activity of overexpressed CD39, a malachite green assay was performed (Figure 1F ) on bone marrow-derived macrophages of WT and transgenic mice. This assay measures generation of inorganic phosphate from precursor substrates. These results demonstrate that phosphohydrolysis of ATP and ADP are significantly elevated in samples containing bone marrow-derived macrophages from transgenic mice compared with WT mice. Complete blood counts were also taken (Table 1 ) from WT and transgenic mice to determine whether any downstream differences could be accounted for by decreased platelet or leukocyte counts at baseline. These results show that across all parameters measured, no significant differences occurred between the 2 groups. Similarly, heart rate and blood pressure were measured in WT, transgenic, and LysM mice before and after MCAO, and no differences were found among these groups at any time point (Figure I in the online-only Data Supplement).
CD39 Mice Are Protected From Effects of Ischemia
Forty-eight hours after the induction of cerebral ischemia, brains were harvested, and ischemic hemispheres were compared to contralateral hemispheres using flow cytometry. Recruitment of macrophages was drastically suppressed in ischemic hemispheres of transgenic mice (Figure 2A) . Similarly, recruitment of neutrophils was also suppressed in the ischemic hemispheres of transgenic mice ( Figure 2B ). Cell counts for total leukocytes, macrophages, and neutrophils in the nonstroke (contralateral) hemisphere did not differ between WT and transgenic mice, but significantly less inflammation occurred in transgenic compared with WT ischemic hemispheres ( Figure 2C ). The suppression of inflammation in ischemic hemispheres of transgenic mice compared with WT mice corresponded to smaller cerebral infarct volumes. In terms of microglia, it seems that EIIA-Cre recombination is low in microglia in comparison to bone marrow-derived macrophages ( Figure II in the online-only Data Supplement), which may indicate that differences observed between WT and transgenic infarcted brains is driven largely by infiltrating as opposed to resident cells. MRI scans obtained from transgenic mice 48 hours after induction of ischemia demonstrated 20% reduced cerebral infarct volumes compared with WT mice (Figure 3A-C) . Mice were scored according to a 5-point neurological deficit scale 48 hours after MCAO. CD39 transgenic mice exhibited less neurological deficit than their WT controls ( Figure 3D ).
CD39 Overexpression Leads to Differential Cytokine Expression After Cerebral Ischemia
Six hours after inducing cerebral ischemia, brains were harvested and contralateral and ipsilateral hemispheres were isolated separately and homogenized to analyze cytokine expression by a multiplex protein array (Figure 4 and Figure III in the online-only Data Supplement). Cytokine/chemokine expression levels in contralateral hemispheres of WT and transgenic mice were not different from each other. However, ischemic hemispheres of WT mice showed elevated levels of proinflammatory cytokines and chemokines. Classically designated anti-inflammatory cytokines showed mixed patterns of expression. Interleukin-4 (IL-4) showed no significant differences between any of the hemispheres, whereas WT ipsilateral hemispheres showed greater IL-5 expression compared with transgenic ipsilateral hemispheres. IL-6 was also more highly expressed in ischemic WT cerebral hemispheres. TNF-α was elevated in WT ipsilateral (ischemic) hemispheres and conversely suppressed in transgenic mice. TNF-α expression across both ischemic and nonischemic hemispheres in WT and transgenic mice was visualized ( Figure 5A ). TNF-α expression in the ischemic hemisphere of transgenic mice was lower relative to the WT mouse. CD39 was elevated in the transgenic mouse compared with WT mice as expected.
Because ATP is a substrate for both the P2Y and P2X families of purinergic receptors, but the P2X7 receptor is specifically activated at the high concentrations of extracellular ATP (>100 μM) present in points of inflammation and damaged tissue, 28, 29 we next examined the expression of P2X7 in this model. Figure 5B shows the distribution of P2X7 receptors after stroke. P2X7 receptor is widely expressed in macrophages and other circulating leukocytes, 30 and it was seen in the ischemic hemispheres of both mice, whereas nonischemic hemispheres appeared unaffected. Figure 5C shows coronal sections of tissuespecific, LysM-Cre/CD39 transgenic mice. These mice overexpress CD39 in a tissue-specific manner in LysM cells only. After 48 hours of stroke, the area affected by MCAO was much smaller in LysM-Cre transgenic mouse brains. It is important to note that no difference in CD39 expression was discovered between the contralateral hemispheres of WT and LysM-Cre transgenic mice.
MRI scans were performed on LysM-Cre transgenic mice 48 hours after MCAO ( Figure 6A ). As with globally CD39-overexpressing transgenic mice, CD39-LysM-Cre transgenic mice were protected. LysM-Cre transgenic mice exhibited smaller cerebral infarct volumes compared with WT mice ( Figure 6B ). To assess the longer term impact of myeloid cell-restricted overexpression of CD39 on cerebral infarct volumes, both WT and CD39-LysM-Cre transgenic mice were subjected to MCAO and their brains analyzed 1 week later ( Figure 6C and D) . The protective effect of myeloid overexpression of CD39 was also observed 1 week after MCAO, where LysM-Cre transgenic mice exhibited smaller cerebral infarct volumes compared with WT mice.
DISCUSSION
Although some effective fibrinolytic and antiplatelet treatments promote reperfusion in ischemic brain tissue, alternative approaches remain a priority because current treatments are limited and associated with complications such as an increased risk of intracerebral hemorrhage. Treatment with fibrinolytics is confined to a narrow time frame in which the neurological benefit outweighs the risk of bleeding, a maximum of only 4.5 hours from symptom onset. 31 As a result, only a small portion of those with ischemic stroke benefit from this intervention.
1 Reperfusion injury to the ischemic region is a well-known risk of thrombolytic treatment and can result in cellular death, edema, and necrosis, and may exacerbate tissue damage. [32] [33] [34] Increased leukocyte infiltration and release of reactive oxygen species, as well as increased platelet activation contribute to this injury. 34, 35 Therefore, the search for more selective methods of controlling the brain tissue response to ischemia continues, wherein anti-thrombotic and anti-inflammatory mechanisms can be used in a cell-specific and directed manner. The model used in this study investigates the actions of CD39 in the absence of reperfusion and thus aims to demonstrate the efficacy of CD39 overexpression on limiting inflammation and infarct size because of ischemia.
Previous work has readily established CD39 as a strong mediator of thrombosis and inflammation. 12, [36] [37] [38] ATP and ADP, potent triggers of inflammation and thrombosis, respectively, can be present at high concentrations in localized areas of tissue damage. This initial proinflammatory signal of ATP, which occurs with even minor perturbations of the cellular membrane, is the activity CD39 is positioned to dissipate. The apyrase activity of CD39 cleaves ATP and ADP to AMP, and the coexpressed partner enzyme of CD39, CD73, completes Middle cerebral arteries of wild type (WT) and transgenic mice were occluded, and 48 hours later left and right cerebral hemispheres were harvested for further analysis by flow cytometry. Cells were then stained with F4/80 (FITC) and CD45 (PE) (A) to identify macrophages and Ly6g (FITC) and CD45 (PE) (B) to identify neutrophils. Data were analyzed using a t test with Welch's modification. Four mice were analyzed for each group. C, Leukocytes were purified of myelin and cellular debris, and total leukocyte counts were obtained. Data were analyzed using a mixed-effect linear regression model. Six mice were analyzed for each group. *P<0.05. the cleavage of AMP to adenosine, which modulates inflammation and may protect against ischemic injury.
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Combined with our work, which uses a permanent occlusion model, this finding suggests that CD39 or its downstream signaling pathway has a high therapeutic potential to limit ischemic brain injury.
Confirmation of the Transgenic Mouse Design
We developed a transgenic mouse that globally expresses elevated levels of CD39, which has the potential to be used to generate other cell-specific CD39-overexpressing mice, to express elevated levels of CD39 in specific tissues. To accomplish this goal, a vector containing a floxed stop sequence between the promoter and the transcriptional start sequence of human CD39
was obtained, such that in the presence of the enzyme Cre recombinase, 43, 44 the stop sequence would be deleted and expression of human CD39 would be driven by a CAG promoter/enhancer sequence. This mouse was developed to aid in future studies of CD39 that center on questions of the role of CD39 in specific tissues and further characterization of CD39 function across different disease models. We have demonstrated that in our CD39 transgenic mice, human CD39 is detectable in DNA, RNA, and protein samples. We are able to distinguish between the endogenous and transgene at the RNA level, and furthermore we can see that this additional expression of CD39 elevates the total CD39 protein across a panel of different tissues.
Having confirmed the expected genotype, protein, and RNA expression for the globally transgenic mice, we have shown that CD39 overexpression is functional at baseline, as bone marrow-derived macrophages from transgenic mice exhibited more apyrase activity compared with WT mice. Our studies have shown that this baseline difference in apyrase activity conferred a protective effect in transgenic mice against inflammation and tissue death Middle cerebral arteries of wild type (WT) and transgenic mice were occluded, and 6 hours later left and right cerebral hemispheres were harvested and total protein purified. A panel of cytokine levels was measured using a multiplex bead assay. Cytokine levels in ischemic (ipsilateral) hemispheres were compared to contralateral hemispheres (n=3 mice for each group). Data were analyzed using a mixed-effect linear regression model with a Bonferroni correction. *P<0.0025. after a cerebral ischemic insult. Most intriguing, it can be seen that mice which overexpress CD39, specifically in their LysM cells, are also protected in terms of infarct size. The mice used in this study were adult mice (mean 10 weeks of age). Future experiments with older mice, female mice, or mice with hyperlipidemia or hypertension could broaden the applicability of our findings.
In the globally CD39 transgenic mice, although the proportions of infiltrating macrophages and neutrophils were not affected, total inflammation was significantly decreased in the first 48 hours after stroke. This difference was confirmed by MRIs showing a far smaller stroke volume, as well as by neurological scoring reflecting fewer neurological deficits in transgenic compared with WT mice. The time points examined in this study are within the time frame in which inflammation has been shown to be increasing after MCAO. 45, 46 We investigated whether the smaller infarct volumes observed in transgenic mice were accompanied by expression patterns of cytokines previously demonstrated to be important drivers of tissue damage in cerebral ischemia. A multiplex cytokine array was chosen because it allows the simultaneous and highly sensitive measurement of many cytokines from the same samples under the same experimental conditions, thereby giving more consistent and reliable measurements within the sample set. 47 Measuring many cytokines of interest together, rather than focusing on just a limited few, presents a Figure 5 . Expression of tumor necrosis factor-α (TNF-α) and P2X7 receptor in brains after stroke.
Middle cerebral arteries of wild type (WT) and transgenic mice were occluded and later frozen in OCT at either 6 or 48 hours after middle cerebral artery occlusion. Coronal sections of transgenic and WT mouse brains were stained for (A) TNF-α shown in green and CD39 shown in red 6 hours after occlusion, (B) P2X7 receptor shown in green and CD39 shown in red 6 hours after occlusion, and (C) P2X7 receptor shown in green and CD39 shown in red 48 hours after occlusion in LysM-Cre/CD39 transgenic mice. DAPI was used as a counterstain in all panels.. complete representation of inflammatory mediators within the tissue. Concordant with the anatomic cerebral and functional protection in stroke conferred by transgenic overexpression of CD39, data from a cytokine/ chemokine array performed on tissue from mice after ischemic stroke revealed a less inflammatory phenotype after stroke in CD39 transgenic mice. A general pattern of cytokine expression manifested. Across classically proinflammatory cytokines, levels in CD39 transgenic ischemic hemispheres were uniformly lower than in the WT ischemic hemispheres. Contralateral nonischemic hemispheres, in contrast, which served as controls, did not appear to differ between the 2 genotypes.
In summary, these data support a generally antiinflammatory state in the transgenic human CD39-overexpressing mice we have developed compared with WT mice, even when challenged with a profound interruption of blood supply to a critical brain region. The mice we have generated do not appear to be phenotypically different from WT mice in any of the parameters tested, thus supporting our hypothesis that CD39 overexpression can protect against central nervous system inflammation and tissue death. The role of TNF-α in models of cerebral ischemia remains debated. The onset of cerebral ischemia is marked by an immediate increase in levels of TNF-α within 1 to 3 hours of injury, followed by a second peak at 24 to 36 hours, [48] [49] [50] and microglia and infiltrating leukocytes are largely responsible for this response. 51 Whereas elevated levels of TNF-α in acute stroke have been associated with impaired survival, inhibition of TNF-α in the long term has been shown to impede repair. [52] [53] [54] Elevation of TNF-α has been shown to increase cerebral infarct volumes in a model of cerebral ischemia, 55 whereas tolerance to ischemic injury by ischemic preconditioning is associated with elevated TNF-α expression. 56 In this current study, we found that elevated TNF-α was associated with greater ischemic damage, and that the overexpression of CD39 suppressed inflammation. This finding was associated with diminished expression of TNF-α in the ischemic hemisphere of transgenic mouse brains. The decreased TNF-α expression at early ischemic time points in transgenic mice was seen in both direct measurements of the cytokine in ischemic tissue, as well as in staining of coronal brain sections. In these samples, the ischemic hemispheres of transgenic mice contain less TNF-α, but the expression of TNF-α was localized to a much smaller area relative to WT mice.
Future therapies derived from understanding CD39 and its physiological roles may offer an alternative to currently available thienopyridine antiplatelet therapies, which disable platelet function by binding P2Y12 receptors. This is because CD39 phosphohydrolyzes ADP, the substrate of P2Y12 receptors, and so mitigates platelet activation indirectly. Our previously published work has demonstrated that upregulation of endogenous CD39 is possible through the use of PDEIII-inhibiting drugs that are clinically used, 57, 58 which gives further translational relevance to our findings in this article. In the future, repurposing of existing drugs may be used to drive expression of the endogenous CD39 gene, or delivery of compounds that mimic CD39 phosphohydrolytic activity may be an alternative strategy. In either case, the studies presented here suggest that catalytic cleave of purinergic nucleotides could represent an important therapeutic target in stroke.
